Innate Immune

INmune Bio is a clinical-stage biotechnology company dedicated to reprogramming the innate immune system to treat cancer and neurodegenerative diseases. The company's lead candidate, XPro (pegipanermin), is a next-generation TNF inhibitor designed to neutralize soluble TNF (sTNF) to reduce neuroinflammation in Alzheimer's disease without suppressing the protective effects of transmembrane TNF. Its oncology platform, INKmune, focuses on priming a patient's own natural killer (NK) cells to eliminate residual cancer cells in both hematologic and solid tumors. Additionally, the company is developing CORDStrom, a mesenchymal stem cell platform for rare skin diseases. INmune Bio aims to restore normal immune function to allow the body to heal itself across a broad range of chronic conditions.